One of them is E75, a breast cancer vaccine that uses the immunologic adjuvant GM-CSF to target the HLA-A2/A3-restricted, HLA class-I, extracellular HER2-derived peptide E75.It is one of the most studied epitope-based vaccines that was identified in 1995 [94]. Here, ERBB2 is linked to breast carcinoma.